Oncogenes and angiogenesis

A way to personalize anti-angiogenic therapy?

Alessia Bottos, Alberto Bardelli

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The acquisition of oncogenic mutations and promotion of angiogenesis are key hallmarks of cancer. These features are often thought of as separate events in tumor progression and the two fields of research have frequently been considered as independent. However, as we highlight in this review, activated oncogenes and deregulated angiogenesis are tightly associated, as mutations in cancer cells can lead to perturbation of the pro- and anti-angiogenic balance thereby causing aberrant angiogenesis. We propose that normalization of the vascular network by targeting oncogenes in the tumor cells might lead to more efficient and sustained therapeutic effects compared to therapies targeting tumor vessels. We discuss how pharmacological inhibition of oncogenes in tumor cells restores a functional vasculature by bystander anti-angiogenic effect. As genetic alterations are tumor-specific, targeted therapy, which potentially blocks the angiogenic program activated by individual oncogenes may lead to personalized anti-angiogenic therapy.

Original languageEnglish
Pages (from-to)4131-4140
Number of pages10
JournalCellular and Molecular Life Sciences
Volume70
Issue number21
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Oncogenes
Neoplasms
Therapeutics
Mutation
Therapeutic Uses
Blood Vessels
Pharmacology
Research

Keywords

  • Angiogenesis
  • Anti-angiogenic therapy
  • Oncogenes
  • Targeted therapy
  • Vessel normalization

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Molecular Medicine
  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Oncogenes and angiogenesis : A way to personalize anti-angiogenic therapy? / Bottos, Alessia; Bardelli, Alberto.

In: Cellular and Molecular Life Sciences, Vol. 70, No. 21, 11.2013, p. 4131-4140.

Research output: Contribution to journalArticle

@article{ad63ae89e6e14792897fdac3a5923c15,
title = "Oncogenes and angiogenesis: A way to personalize anti-angiogenic therapy?",
abstract = "The acquisition of oncogenic mutations and promotion of angiogenesis are key hallmarks of cancer. These features are often thought of as separate events in tumor progression and the two fields of research have frequently been considered as independent. However, as we highlight in this review, activated oncogenes and deregulated angiogenesis are tightly associated, as mutations in cancer cells can lead to perturbation of the pro- and anti-angiogenic balance thereby causing aberrant angiogenesis. We propose that normalization of the vascular network by targeting oncogenes in the tumor cells might lead to more efficient and sustained therapeutic effects compared to therapies targeting tumor vessels. We discuss how pharmacological inhibition of oncogenes in tumor cells restores a functional vasculature by bystander anti-angiogenic effect. As genetic alterations are tumor-specific, targeted therapy, which potentially blocks the angiogenic program activated by individual oncogenes may lead to personalized anti-angiogenic therapy.",
keywords = "Angiogenesis, Anti-angiogenic therapy, Oncogenes, Targeted therapy, Vessel normalization",
author = "Alessia Bottos and Alberto Bardelli",
year = "2013",
month = "11",
doi = "10.1007/s00018-013-1331-3",
language = "English",
volume = "70",
pages = "4131--4140",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
number = "21",

}

TY - JOUR

T1 - Oncogenes and angiogenesis

T2 - A way to personalize anti-angiogenic therapy?

AU - Bottos, Alessia

AU - Bardelli, Alberto

PY - 2013/11

Y1 - 2013/11

N2 - The acquisition of oncogenic mutations and promotion of angiogenesis are key hallmarks of cancer. These features are often thought of as separate events in tumor progression and the two fields of research have frequently been considered as independent. However, as we highlight in this review, activated oncogenes and deregulated angiogenesis are tightly associated, as mutations in cancer cells can lead to perturbation of the pro- and anti-angiogenic balance thereby causing aberrant angiogenesis. We propose that normalization of the vascular network by targeting oncogenes in the tumor cells might lead to more efficient and sustained therapeutic effects compared to therapies targeting tumor vessels. We discuss how pharmacological inhibition of oncogenes in tumor cells restores a functional vasculature by bystander anti-angiogenic effect. As genetic alterations are tumor-specific, targeted therapy, which potentially blocks the angiogenic program activated by individual oncogenes may lead to personalized anti-angiogenic therapy.

AB - The acquisition of oncogenic mutations and promotion of angiogenesis are key hallmarks of cancer. These features are often thought of as separate events in tumor progression and the two fields of research have frequently been considered as independent. However, as we highlight in this review, activated oncogenes and deregulated angiogenesis are tightly associated, as mutations in cancer cells can lead to perturbation of the pro- and anti-angiogenic balance thereby causing aberrant angiogenesis. We propose that normalization of the vascular network by targeting oncogenes in the tumor cells might lead to more efficient and sustained therapeutic effects compared to therapies targeting tumor vessels. We discuss how pharmacological inhibition of oncogenes in tumor cells restores a functional vasculature by bystander anti-angiogenic effect. As genetic alterations are tumor-specific, targeted therapy, which potentially blocks the angiogenic program activated by individual oncogenes may lead to personalized anti-angiogenic therapy.

KW - Angiogenesis

KW - Anti-angiogenic therapy

KW - Oncogenes

KW - Targeted therapy

KW - Vessel normalization

UR - http://www.scopus.com/inward/record.url?scp=84887121023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887121023&partnerID=8YFLogxK

U2 - 10.1007/s00018-013-1331-3

DO - 10.1007/s00018-013-1331-3

M3 - Article

VL - 70

SP - 4131

EP - 4140

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 21

ER -